

ULISSE BIOMED S.P.A.

**NOTIFICATI A CONSOB I KID – “KEY INFORMATION DOCUMENT” RELATIVI AI
“WARRANT ULISSE BIOMED S.P.A. 2021-2026” E AGLI “SHORT-RUN WARRANT
ULISSE BIOMED S.P.A. 2021”**

Trieste, 4 agosto 2021

Ulisse Biomed S.p.A. (“**UBM**” o la “**Società**”), *healthcare biotech company* italiana attiva nei settori della diagnostica, teranostica e nel campo terapeutico, comunica di aver notificato in data odierna a Consob i KID (Key Information Document) relativi ai “WARRANT *ULISSE BIOMED S.P.A. 2021-2026*” e agli “*SHORT-RUN WARRANT ULISSE BIOMED S.P.A. 2021*” come previsto dall’art. 4 decies del TUF con riferimento ai PRIIPs (Packaged Retail and Insurance-based Investment Products), di cui al Regolamento UE n.1286/2014.

Il KID, documento informativo sintetico e standardizzato predisposto in base al Regolamento Europeo in materia di PRIIPs relativo ai prodotti d’investimento al dettaglio e assicurativi pre- assemblati, raffigura all’investitore le caratteristiche del prodotto d’investimento in modo semplice e comprensibile, rendendo comparabili i diversi prodotti finanziari ed aumentando il grado di trasparenza delle informazioni.

I KID sui “WARRANT *ULISSE BIOMED S.P.A. 2021-2026*” e sugli “*SHORT-RUN WARRANT ULISSE BIOMED S.P.A. 2021*” sono a disposizione del pubblico presso la sede legale della Società e nella sezione Investor Relations del sito internet <http://ulissebiomed.com>.

Per maggiori informazioni

Investor Relations
Matteo Petti
Tel. +39 040 3757540
m.petti@ulissebiomed.com

Nomad, Specialist e Corporate Broker
BPER Banca S.p.A
Via Negri 10, Milano
ubm@bper.it

Maggiori dettagli su
www.ulissebiomed.com

Ulisse Biomed è una *healthcare biotech company* operante nei settori della diagnostica, della teranostica e della terapeutica con l'obiettivo di sviluppare soluzioni innovative in detti campi. L'azienda dispone di tre piattaforme tecnologiche proprietarie in grado di generare prodotti innovativi e competitivi: Sagitta (diagnostica molecolare), NanoHybrid (teranostica e diagnostica) e Aptavir (terapeutica). UBM è titolare di un portafoglio di *intellectual properties* costituito da 8 domande di brevetto internazionali (3 relative a Sagitta, 2 relative a NanoHybrid, 1 relativa a Aptavir e 2 trasversali alle tre piattaforme), due dei quali concessi in Italia ed in Europa, che coprono le tre piattaforme tecnologiche.

ULISSE BIOMED S.P.A.

THE KID – “KEY INFORMATION DOCUMENTS” RELATING TO THE “WARRANT ULISSE BIOMED S.P.A. 2021-2026” and to the “SHORT-RUN WARRANT ULISSE BIOMED S.P.A. 2021” HAVE BEEN COMMUNICATED TO CONSOB

Trieste, August 4th, 2021

Ulisse Biomed S.p.A. (“**UBM**” or the “**Company**”), Italian healthcare biotech company active in diagnostics, theranostics and therapeutics with the mission to provide innovative solutions in these fields, announces having communicated today the KID (Key Information Documents) relating to the “WARRANT *ULISSE BIOMED S.P.A. 2021-2026*” and to the “SHORT-RUN WARRANT *ULISSE BIOMED S.P.A. 2021*” to Consob, as required by art. 4 decies of the TUF (Consolidated Law on Finance) with reference to the PRIIPs (Packaged Retail and Insurance-based Investment Products), referred to in EU Regulation no. 1286/2014.

The KID, a synthetic and standardized information document prepared on the basis of European Regulation on PRIIPs relating to pre-assembled retail and insurance investment products, represents the characteristics of the investment product to the investor in a simple and understandable way, making comparable the different financial products and increasing the information transparency level.

The KID relating to “Warrant Osai A.S. S.p.A. 2020-2025” and “Short-run Warrant Osai A.S. S.p.A. 2020” are available at the Company's registered office and on the Investor Relations section of the Company's website: <http://www.ulissebiomed.com>.

For further information

Investor Relations
Matteo Petti
Tel. +39 040 3757540
m.petti@ulissebiomed.com

Nomad, Specialist e Corporate Broker
BPER Banca S.p.A
Via Negri 10, Milano
ubm@bper.it

Further details at
www.ulissebiomed.com

Ulisse Biomed is a healthcare biotech company operating in diagnostics, theranostics and therapeutics with the mission to develop innovative solutions in these fields. The company has three proprietary technology platforms capable of generating innovative and competitive products: Sagitta (molecular diagnostics), NanoHybrid (theranostics and diagnostics) and Aptavir (therapeutics). UBM owns a portfolio of intellectual properties made of 8 international patent applications that cover the three technology platforms (3 related to Sagitta, 2 related to NanoHybrid, 1 related to Aptavir and 2 transversal to the three platforms), two of them are granted in Italy and in Europe.